Please select the option that best describes you:
Are there any scenarios in which you would consider use of PARPi in the upfront mCSPC setting rather than reserving for CRPC?
Answer from: Medical Oncologist at Community Practice
The FDA approved talazoparib plus enzalutamide for HRRm metastatic CRPC in June 2023. NCCN panel recommends talazoparib plus enzalutamide as a category 1 treatment option for patients with metastatic CRPC and a pathogenic mutation (germline and/or somatic) in one of certain HRR and other DNA repair ...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
Not at this time until more data is released from the ongoing studies such as AMPLITUDE/TALAPRO-3 are published. There are risks of serious bone marrow toxicity such as bone marrow failure, leukemia, and myelodysplastic syndrome with PARPi. (1) Presumably this risk is dose-related and duration-relat...
Answer from: at Community Practice
Currently, the only scenario which I would consider is a well designed clinical trial.